3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
2
Lymphoma
2
Neoplasm Metastasis
1
Myasthenia Gravis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Hepatocellular
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
rozanolixizumab
7
zilucoplan
6
efgartigimod alfa
5
eculizumab
4
telitacicept
3
ravulizumab
3
Tacrolimus
3
Rituximab
3
Amifampridine
3
Prednisone
2
Mycophenolic Acid
2
HBM9161
2
satralizumab
1
remibrutinib
1
iptacopan
1
inebilizumab
1
Thymectomy
1
Sugars
1
Steroids
1
Sodium Chloride
1
Pyridostigmine Bromide
1
Prednisolone
1
Plasmapheresis
1
Leflunomide
1
Immunoglobulins, Intravenous
1
Hizentra
1
Cladribine
1
Azathioprine
1
Alkalies
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Myasthenia Gravis
×
Steroids
×
Clear all
NCT00995722
2017-06-02
EPITOME'
University of Miami
Phase 3
Terminated
11 enrolled
14 charts